Title (en)

EGR1 MODULATORS USED IN THE TREATMENT OF ALOPECIA

Title (de)

BEI DER BEHANDLUNG VON ALOPECIA VERWENDETE EGR1-MODULATOREN

Title (fr)

MODULATEURS DE EGR1 DANS LE TRAITEMENT DE L'ALOPÉCIE

Publication

**EP 2242849 A2 20101027 (FR)**

Application

**EP 08858303 A 20081126**

Priority

- FR 2008052131 W 20081126
- FR 0759323 A 20071126

Abstract (en)

[origin: WO2009071841A2] The invention relates to a method, according to one of Claims 1-6, in which the expression of the gene is determined by measuring the transcription ratio of said gene. The invention also relates to a method, according to one of Claims 1-6, in which the expression of the gene is determined by measuring the translation ratio of said gene. The invention also relates to the use of a modulator of the Early Growth Response 1 transcription factor that can be obtained according to one of Claims 1-8 in order to prepare a drug for the preventive and/or therapeutic treatment of alopecia. The invention also relates to a use according to Claim 9, characterised in that the modulator is an activator of the Early Growth Response 1 transcription factor. The invention also relates to the cosmetic use of a modulator of the Early Growth Response 1 transcription factor for the aesthetic treatment of the scalp. The invention also relates to an in vitro method for diagnosing or following the development of alopecia in a subject, that comprises comparing the expression or the activity of the Early Growth Response 1 protein, or the expression of the gene thereof or the activity of at least one of the promoters thereof in a biological sample from a subject, with a biological sample of a controlled subject. The invention further relates to a method according to Claim 12, in which the expression of the protein is determined by an assay of said protein using an immunoassay. The invention also relates to a method according to Claim 13, in which the immunoassay is an ELISA assay. The invention also relates to a method according to Claim 14, in which the expression of the gene is determined by measuring the amount of the corresponding mRNA.

IPC 8 full level

**C12Q 1/25** (2006.01)

CPC (source: EP US)

**A61P 17/14** (2017.12 - EP); **G01N 33/5088** (2013.01 - EP US); **G01N 33/6872** (2013.01 - EP US); G01N 2800/20 (2013.01 - EP US); G01N 2800/50 (2013.01 - EP US)

Citation (search report)

See references of WO 2009071841A2

Citation (examination)

DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 2005 (2005-11-01), RENDL MICHAEL ET AL: "Molecular dissection of mesenchymal-epithelial interactions in the hair follicle.", Database accession no. NLM16162033 & PLOS BIOLOGY NOV 2005 LNKD- PUBMED:16162033, vol. 3, no. 11, November 2005 (2005-11-01), pages e331, ISSN: 1545-7885

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA MK RS

DOCDB simple family (publication)

**FR 2924128 A1 20090529**; CA 2706672 A1 20090611; EP 2242849 A2 20101027; US 2010260736 A1 20101014; WO 2009071841 A2 20090611; WO 2009071841 A3 20091015

DOCDB simple family (application)

**FR 0759323 A 20071126**; CA 2706672 A 20081126; EP 08858303 A 20081126; FR 2008052131 W 20081126; US 78467210 A 20100521